3 Month Outcome of Ziv-aflibercept for DME

Sponsor
Marashi Eye Clinic
Study ID
NCT02772497
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Ziv aflibercept — DRUG
    Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks

Study Details

The purpose is to show the 3-month efficacy and safety in diabetic macular edema treated with intravitreal ziv-aflibercept.

Key Dates

Start date
Jan 31, 2016
Status verified
Jul 2017
Primary completion
May 31, 2016
Completion
May 31, 2016

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ziv aflibercept
    Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks

Primary Outcome Measure

Proportion of visual acuity improvement using Snellen chart or equivalent [ Time Frame: 3 months ]

Related Studies